{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T21:40:21Z","timestamp":1760996421401,"version":"build-2065373602"},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:title>Abstract:<\/jats:title>\n          <jats:p>Primary cutaneous anaplastic large cell lymphoma (PC-ALCL) belongs to the group of primary cutaneous CD30-positive lymphoproliferative disorders. Its diagnosis requires a multidisciplinary approach, integrating clinical, histopathological, and immunohistochemical findings. Although extracutaneous spread is uncommon in PC-ALCL, locoregional lymph node involvement may occur and can pose significant diagnostic challenges, particularly in distinguishing PC-ALCL from systemic ALCL with secondary skin involvement. PC-ALCL has predilection for the head and neck area, whereas systemic ALCL tend to show more disseminated disease. ALK1 might help in the differential between ALK-positive systemic ALCL and ALK-negative systemic ALCL, but other molecular studies such as <jats:italic toggle=\"yes\">DUSP22<\/jats:italic> and <jats:italic toggle=\"yes\">TP63<\/jats:italic> rearrangement do not aid in the differential diagnosis between PC-ALCL and ALK-negative systemic ALCL. Here, we add 2 new cases of PC-ALCL with nodal disease to the 8 cases previously reported, including one during pregnancy. Both cases presented with a solitary lesion and ipsilateral axillary lymph node involvement. Histological and immunophenotypic features were consistent across skin and lymph node biopsies and supported the diagnosis of primary cutaneous origin and were managed with brentuximab vedotin\u2013based chemotherapy, with favorable clinical responses. We emphasize the importance of thorough clinical staging and histopathological correlation to establish the correct diagnosis and the optimal treatment for cases like ours.<\/jats:p>","DOI":"10.1097\/dad.0000000000003103","type":"journal-article","created":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T15:00:09Z","timestamp":1755183609000},"page":"866-870","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Primary Cutaneous Anaplastic Large Cell Lymphoma with Locoregional Lymph Node Involvement: Challenges in Diagnosis and Clinical Management"],"prefix":"10.1097","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2078-8205","authenticated-orcid":false,"given":"Mar","family":"Garcia-Garcia","sequence":"first","affiliation":[{"name":"Pathology Department, Hospital Cl\u00ednico Universitario Lozano Blesa, Zaragoza, Spain;"},{"name":"Department of Surgery, Unizar, Zaragoza, Spain;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Leticia","family":"Tardin Cardoso","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Department, Hospital Cl\u00ednico Universitario Lozano Blesa, Zaragoza, Spain;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ignacio Sancho","family":"Val","sequence":"additional","affiliation":[{"name":"Hematology Department, Hospital Cl\u00ednico Universitario Lozano Blesa, Zaragoza, Spain;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alejandro Lape\u00f1a","family":"Casado","sequence":"additional","affiliation":[{"name":"Dermatology Department, Hospital Cl\u00ednico Universitario Lozano Blesa, Zaragoza, Spain; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ignacio","family":"Hern\u00e1ndez-Arag\u00fc\u00e9s","sequence":"additional","affiliation":[{"name":"Dermatology Department, Hospital Universitario Miguel Servet, Zaragoza, Spain."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luc\u00eda","family":"Prieto-Torres","sequence":"additional","affiliation":[{"name":"Dermatology Department, Hospital Cl\u00ednico Universitario Lozano Blesa, Zaragoza, Spain; and"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2025,8,14]]},"reference":[{"key":"R1-20251020","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1182\/blood-2018-11-881268","article-title":"The 2018 update of the WHO-EORTC classification for primary cutaneous lymphomas","volume":"133","author":"Willemze","year":"2019","journal-title":"Blood"},{"key":"R3-20251020","doi-asserted-by":"crossref","first-page":"4667","DOI":"10.3390\/cancers13184667","article-title":"ALK-negative anaplastic large cell lymphoma: current concepts and molecular pathogenesis of a heterogeneous group of large T-cell lymphomas","volume":"13","author":"Pina-Oviedo","year":"2021","journal-title":"Cancers"},{"key":"R4-20251020","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1097\/DAD.0000000000002084","article-title":"Primary cutaneous anaplastic large cell lymphoma with 6p25.3 rearrangement and epidermotropism","volume":"44","author":"Dutra","year":"2022","journal-title":"Am J Dermatopathol"},{"key":"R5-20251020","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/S0140-6736(17)31266-7","article-title":"Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial","volume":"390","author":"Prince","year":"2017","journal-title":"Lancet"},{"key":"R6-20251020","doi-asserted-by":"crossref","first-page":"226","DOI":"10.3324\/haematol.2018.197152","article-title":"CD30-positive primary cutaneous lymphoproliferative disorders: molecular alterations and targeted therapies","volume":"104","author":"Prieto-Torres","year":"2019","journal-title":"Haematologica"},{"key":"R7-20251020","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1097\/PAS.0b013e3182487158","article-title":"Nodal involvement by cutaneous CD30-positive T-cell lymphoma mimicking classical Hodgkin lymphoma","volume":"36","author":"Eberle","year":"2012","journal-title":"Am J Surg Pathol."},{"key":"R8-20251020","doi-asserted-by":"crossref","first-page":"3653","DOI":"10.1182\/blood.V95.12.3653","article-title":"Primary and secondary cutaneous CD30(+) lymphoproliferative disorders: a report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment","volume":"95","author":"Bekkenk","year":"2000","journal-title":"Blood"},{"key":"R9-20251020","doi-asserted-by":"crossref","first-page":"132","DOI":"10.14740\/jh534","article-title":"Combined modality treatment with brentuximab vedotin and radiation therapy for primary cutaneous anaplastic large cell lymphoma: a case report","volume":"8","author":"Floyd","year":"2019","journal-title":"J Hematol."},{"key":"R10-20251020","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1097\/DAD.0000000000000908","article-title":"Primary cutaneous small cell variant of anaplastic large cell lymphoma: a case series and review of the literature","volume":"39","author":"Magro","year":"2017","journal-title":"Am J Dermatopathol"},{"key":"R11-20251020","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1111\/j.1365-4632.2004.02412.x","article-title":"Cutaneous presentation on the eyelid of primary, systemic, CD30+, anaplastic lymphoma kinase (ALK)-negative, anaplastic large-cell lymphoma (ALCL)","volume":"45","author":"Menc\u00eda-Guti\u00e9rrez","year":"2006","journal-title":"Int J Dermatol."},{"key":"R12-20251020","first-page":"331","article-title":"Clinical spectrum of primary cutaneous CD30-positive anaplastic large cell lymphoma: an analysis of the Mannheim Cutaneous Lymphoma Registry","volume":"10","author":"Booken","year":"2012","journal-title":"J Dtsch Dermatol Ges"},{"key":"R13-20251020","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1111\/j.1365-2230.2008.03182.x","article-title":"Primary cutaneous CD30+ anaplastic large-cell lymphoma with generalized skin involvement and involvement of one peripheral lymph node, successfully treated with low-dose oral etoposide","volume":"34","author":"Yamane","year":"2009","journal-title":"Clin Exp Dermatol."},{"key":"R14-20251020","doi-asserted-by":"crossref","first-page":"373","DOI":"10.5999\/aps.2021.00185","article-title":"The management of breast implant-associated anaplastic large cell lymphoma in the setting of pregnancy: seeking for clinical practice guidelines","volume":"48","author":"Elia","year":"2021","journal-title":"Arch Plast Surg."},{"key":"R15-20251020","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1046\/j.1365-2257.2000.00144.x","article-title":"Leukaemic small cell variant anaplastic large cell lym-phoma during pregnancy","volume":"22","author":"Lesesve","year":"2000","journal-title":"Clin Lab Haematol."},{"key":"R16-20251020","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1007\/BF02982003","article-title":"Pregnancy-associated cytotoxic lymphoma: a report of 4 cases","volume":"74","author":"Kato","year":"2001","journal-title":"Int J Hematol."},{"key":"R17-20251020","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1002\/dc.20442","article-title":"Pregnancy-associated anaplastic large-cell lymphoma of the breast: a rare mimic of ductal carcinoma","volume":"34","author":"Iyengar","year":"2006","journal-title":"Diagn Cytopathol"},{"key":"R18-20251020","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1080\/01443610600930621","article-title":"A rare and potentially fatal cause of pelvic pain in pregnancy: anaplastic large cell lymphoma","volume":"26","author":"Alalade","year":"2006","journal-title":"J Obstet Gynaecol."},{"key":"R19-20251020","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1007\/s00296-008-0543-6","article-title":"Anaplastic large cell lymphoma presenting with symmetric polyarthritis in pregnancy","volume":"28","author":"Kisacik","year":"2008","journal-title":"Rheumatol Int."}],"container-title":["The American Journal of Dermatopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/DAD.0000000000003103","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T21:00:17Z","timestamp":1760994017000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/DAD.0000000000003103"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,14]]},"references-count":18,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/dad.0000000000003103","relation":{},"ISSN":["0193-1091","1533-0311"],"issn-type":[{"value":"0193-1091","type":"print"},{"value":"1533-0311","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,14]]}}}